Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AZD2693 phase 2b trial in PNPLA3-risk non-cirrhotic NASH with fibrosis
CTR20232127Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Jul 2023
- Modality
- Antisense Oligonucleotides (ASOs) → Long RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Single-strand DNA → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics, Modified DNA Oligonucleotides → Antisense DNA → DNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of AZD2693 in metabolic dysfunction-associated steatohepatitis (MASH), sponsored by AstraZeneca. Started Jul 2023; status: completed.
02
Drugs
AZD2693
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on CTR20232127.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20232127.